DOD Neurofibromatosis New Investigator Award

The summary for the DOD Neurofibromatosis New Investigator Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD Neurofibromatosis New Investigator Award: The NFRP New Investigator Award (NIA) mechanism was first offered in FY99. Since that time, 266 NIA applications have been received and 36 have been recommended for funding. The intent of the NFRP NIA is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Experience in NF research is allowed, but not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. To be eligible for this award, PIs must meet the eligibility requirements specified below in Section I.C. NIA proposals must include preliminary data originating from the PI, research team, or collaborator that is relevant to NF and the proposed project. Areas of Encouragement (Revised for FY09): The FY09 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas: - Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities; DOD Neurofibromatosis New Investigator Award 3 - Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain; - Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and - Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF. Clinical trials are not allowed under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. See the Program Announcement for the full Funding Opportunity Description.